LITE vs. ESPR
LITE (Lumentum Holdings Inc.) and ESPR (Esperion Therapeutics, Inc.) are both stocks. LITE operates in Communication Equipment (Technology), while ESPR operates in Biotechnology (Healthcare). Over the past 10 years, LITE returned 43.74%/yr vs -14.95%/yr for ESPR. At a 0.20 correlation, their price movements are largely independent.
Performance
LITE vs. ESPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, LITE achieves a 150.02% return, which is significantly higher than ESPR's -14.86% return. Over the past 10 years, LITE has outperformed ESPR with an annualized return of 43.74%, while ESPR has yielded a comparatively lower -14.95% annualized return.
LITE
- 1D
- 3.59%
- 1M
- -10.56%
- YTD
- 150.02%
- 6M
- 184.13%
- 1Y
- 977.85%
- 3Y*
- 158.28%
- 5Y*
- 62.72%
- 10Y*
- 43.74%
ESPR
- 1D
- 0.00%
- 1M
- 0.96%
- YTD
- -14.86%
- 6M
- -18.18%
- 1Y
- 162.50%
- 3Y*
- 35.36%
- 5Y*
- -34.62%
- 10Y*
- -14.95%
LITE vs. ESPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
LITE Lumentum Holdings Inc. | 150.02% | 339.06% | 60.15% | 0.48% | -50.68% | 11.57% | 19.55% | 88.76% | -14.09% | 26.52% |
ESPR Esperion Therapeutics, Inc. | -14.86% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -56.40% | 29.63% | -30.13% | 425.88% |
Correlation
The correlation between LITE and ESPR is 0.14, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.14 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.19 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.17 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.20 |
Correlation (All Time) Calculated using the full available price history since Aug 4, 2015 | 0.20 |
Fundamentals
LITE:
$88.65B
ESPR:
$791.76M
LITE:
$5.26
ESPR:
-$0.03
LITE:
30.95
ESPR:
1.75
LITE:
$2.49B
ESPR:
$418.24M
LITE:
$938.50M
ESPR:
$226.32M
LITE:
$470.10M
ESPR:
$77.18M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
LITE vs. ESPR — Risk / Return Rank
LITE
ESPR
LITE vs. ESPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Lumentum Holdings Inc. (LITE) and Esperion Therapeutics, Inc. (ESPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| LITE | ESPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +9.67 | ||
| Sortino ratioReturn per unit of downside risk | +2.56 | ||
| Omega ratioGain probability vs. loss probability | 1.71 | 1.36 | +0.35 |
| Calmar ratioReturn relative to maximum drawdown | 34.43 | 3.07 | +31.35 |
| Martin ratioReturn relative to average drawdown | 126.26 | 7.68 | +118.58 |
Loading charts...
Drawdowns
LITE vs. ESPR - Drawdown Comparison
The maximum LITE drawdown since its inception was -66.89%, smaller than the maximum ESPR drawdown of -99.37%. Use the drawdown chart below to compare losses from any high point for LITE and ESPR.
Loading charts...
Drawdown Indicators
| LITE | ESPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -66.89% | -99.37% | +32.48% |
Max Drawdown (1Y)Largest decline over 1 year | -28.70% | -53.19% | +24.49% |
Max Drawdown (3Y)Largest decline over 3 years | -50.63% | -80.94% | +30.31% |
Max Drawdown (5Y)Largest decline over 5 years | -66.48% | -97.16% | +30.68% |
Max Drawdown (10Y)Largest decline over 10 years | -66.89% | -99.10% | +32.21% |
Current DrawdownCurrent decline from peak | -12.49% | -97.27% | +84.78% |
Average DrawdownAverage peak-to-trough decline | -23.57% | -69.99% | +46.42% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.81% | 21.30% | -13.49% |
Volatility
LITE vs. ESPR - Volatility Comparison
Lumentum Holdings Inc. (LITE) has a higher volatility of 28.12% compared to Esperion Therapeutics, Inc. (ESPR) at 1.06%. This indicates that LITE's price experiences larger fluctuations and is considered to be riskier than ESPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| LITE | ESPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 28.12% | 1.06% | +27.06% |
Volatility (6M)Calculated over the trailing 6-month period | 69.73% | 61.44% | +8.29% |
Volatility (1Y)Calculated over the trailing 1-year period | 86.47% | 92.66% | -6.19% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 59.94% | 91.79% | -31.85% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 56.62% | 84.61% | -27.99% |
Dividends
LITE vs. ESPR - Dividend Comparison
Neither LITE nor ESPR has paid dividends to shareholders.
Financials
LITE vs. ESPR - Financials Comparison
This section allows you to compare key financial metrics between Lumentum Holdings Inc. and Esperion Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
LITE vs. ESPR - Profitability Comparison
LITE - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported a gross profit of 357.00M and revenue of 808.40M. Therefore, the gross margin over that period was 44.2%.
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
LITE - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported an operating income of 174.50M and revenue of 808.40M, resulting in an operating margin of 21.6%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
LITE - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Lumentum Holdings Inc. reported a net income of 144.20M and revenue of 808.40M, resulting in a net margin of 17.8%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
Frequently Asked Questions
LITE and ESPR have a correlation of 0.14, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
LITE has higher volatility (28.12%) compared to ESPR (1.06%). In terms of maximum drawdown, LITE dropped -66.89% vs ESPR's -99.37%.
LITE currently has the higher Sharpe Ratio (11.43 vs 1.76), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for LITE and ESPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer